| Name | Cinepazide maleate |
| Description | Cinepazide maleate (MD-67350), a maleate salt form of cinepazide, is a vasodilator. |
| In vitro | Cinepazide exhibits strong chronotropic and inotropic effects. Intravenous administration of Cinepazide (1 mg/kg - 3 mg/kg) leads to an 8% increase in heart rate while reducing blood pressure by 4%. Cinepazide selectively enhances the functional activity of 5-HT neurons in the brain, although hypoxia inhibits its activity. Doses of Cinepazide (3 mg/kg - 30 mg/kg) administered intravenously transiently increase renal and femoral arterial blood flow, spinal and carotid blood flow, and cardiac output in anesthetized dogs while decreasing total peripheral resistance, exhibiting a concentration-dependent relationship with these effects. At 30 mg/kg, Cinepazide enhances the dilatory neural response of dog spinal blood vessels to intrathecal adenosine and adenylic acid. Cinepazide (1 mg - 10 mg) amplifies blood flow within spinal vessels in a dose-dependent manner, partially inhibited by pretreatment with intravenous aminophylline and unaffected by autonomic antagonists. Cinepazide is well absorbed, with over 60% excreted within 24 hours. Over five days, the excretion of Cinepazide through feces and urine is 58.3% and 36.7% in rats, 68.6% and 33.4% in dogs, and 38.1% and 61.3% in humans, respectively. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : 98 mg/mL (183.7 mM)
DMSO : 99 mg/mL (185.5 mM)
|
| Keywords | Calcium Channel | stroke | Inhibitor | brain?infarct | Cinepazide Maleate | Ca2+ channels | Cinepazide | piperazine derivative | Ca channels | MD 67350 | vasodilator | Cinepazide maleate | cerebrovascular disease | ischemic | MD67350 | inhibit |
| Inhibitors Related | Nisoldipine | Nimodipine | 2,5-Di-tert-butylhydroquinone | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | Lanthanum(III) chloride heptahydrate | Ethyl cinnamate | 1-Octanol | Otilonium bromide |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
